Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis
Language English Country United States Media print
Document type Practice Guideline, Journal Article
PubMed
38388147
DOI
10.1016/j.kint.2023.10.009
PII: S0085-2538(23)00745-7
Knihovny.cz E-resources
- Keywords
- ANCA-associated vasculitis, KDIGO, glomerular diseases, glomerulonephritis, guideline, systematic review,
- MeSH
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis * diagnosis drug therapy MeSH
- Glomerulonephritis * diagnosis drug therapy MeSH
- Glucocorticoids therapeutic use MeSH
- Kidney MeSH
- Humans MeSH
- Nephrology * MeSH
- Antibodies, Antineutrophil Cytoplasmic MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Practice Guideline MeSH
- Names of Substances
- Glucocorticoids MeSH
- Antibodies, Antineutrophil Cytoplasmic MeSH
In 2021, the Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases was published. KDIGO is committed to providing the nephrology community with periodic updates, based on new developments for each disease. For patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), avacopan received regulatory approval in late 2021, leading to this KDIGO guideline update. In addition, the evidence supporting a lower-dose glucocorticoid induction regimen or even complete replacement of glucocorticoids has become stronger. Herein, an executive summary of the most important guideline changes from the AAV chapter is provided as a quick reference.
Department of Internal Medicine The Ohio State University College of Medicine Columbus Ohio USA
Department of Medicine Cumming School of Medicine University of Calgary Calgary Alberta Canada
Division of Nephrology Tufts Medical Center Boston Massachusetts USA
References provided by Crossref.org
